Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of APL-101 in MET-altered Advanced Solid Tumors and NSCLC
2024-514542-37-00Phase 2Authorised
- Sponsor
- Apollomics, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms and central nervous system tumor, sponsored by Apollomics, Inc. Primary endpoints: Maximum tolerated dose (MTD) of APL-101 in Phase 1, Dose-limiting toxicities (DLTs) in Cycle 1 and 4 more. Planned start Jul 2024; status: authorised.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasmscentral nervous system tumor
Beyond the preview
Go deeper on 2024-514542-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514542-37-00.